Review



mouse anti human pmlc2 ser19  (Cell Signaling Technology Inc)


Bioz Verified Symbol Cell Signaling Technology Inc is a verified supplier
Bioz Manufacturer Symbol Cell Signaling Technology Inc manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 86
      Buy from Supplier

    Structured Review

    Cell Signaling Technology Inc mouse anti human pmlc2 ser19
    a – i Physical interventions altering lumen and branch expansions by externally loading intraluminal pressure in on-chip angiogenesis of ECs. a A schematic diagram showing the timeline of the loading and release cycles of intraluminal pressure. b , c Changes of lumens and branches when loaded followed by release of the additional intraluminal pressure. b Representative DIC images. White dotted lines indicate the proximal and distal boundaries of the analyzed luminal region. c Quantification of the changes in luminal area (loading: n = 12; release: n = 11, from 3 independent experiments). d – i Time-lapse analyses of on-chip angiogenesis during the intervention. d Representative serial DIC images at the elapsed time indicated at the top before and after loading and the release of additional intraluminal pressure (top, See also Supplementary Movie ) and kymograph of branch elongation (bottom). In the DIC images, yellow arrows and red lines indicate the trajectory of the tip of the branch and the tip EC displacement, respectively. In the kymograph, red and blue dotted lines indicate time points at which additional intraluminal pressure was loaded and then released, respectively. e Box plots of averaged branch elongation and the individual plots 3 h before (pressure change (−)) and after (load) the 1 st pressure loading and 3 h after its release (release) (left), and the corresponding box and individual plots in the control group without interventions (right) (pressure loading and release: n = 21 from 4 independent experiments, control: n = 19, from 3 independent experiments, See also Supplementary Fig. ). f – i Kymograph showing the dynamics of tip EC movement for 50 min before and 100 min after loading ( f ) and releasing ( h ) additional intraluminal pressure (time=0, dotted red line), and the quantification showing in box plots of averaged tip EC movement speed ( g , each group: n = 13 from 4 independent experiments; i , each group: n = 8 from 4 independent experiments). j – m Pharmacological interventions altering lumen and branch expansions of on-chip angiogenesis of ECs by treatment with Y27632 (top) and Blebbistatin (bottom), and without and with TG treatment of the gel. j Representative fluorescent images of the angiogenic branches. k Representative confocal z-projection images, with magnified images of square areas bound by dots (z-projection) and their corresponding confocal x-y slice images at specific z-portions (slice), showing localization pattern of <t>pMLC2</t> in the angiogenic branches around the area where the de novo vascular lumen (yellow asterisks) develops. l , m , Box plots of branch length (left) and Tip expandability (right), without and with Y27632 ( l ) or Blebbistatin ( m ) and without and with TG treatment of the gel ( l , Y27632 (−) TG (−): n = 117; Y27632 ( + ) TG (−): n = 108; Y27632 ( + ) TG (+): n = 102, from 3 independent experiments, ( m ), Blebbistatin (−) TG (−): n = 39; Blebbistatin (+) TG (−): n = 35; Blebbistatin (+) TG (+): n = 64, from 3 independent experiments). All box plots show the interquartile range, with the middle line defining the median, and whiskers show the minimum and maximum values, excluding outliers ( g , i , l , m ). Outlier values are defined as being 1.5 times the interquartile range above and below the third and first quartile, respectively. Scale bars: 20 µm ( d , k ), 25 µm ( b ) and 100 µm ( j ). Two-sided Wilcoxon signed rank test ( c ), Wilcoxon signed rank test with a Bonferroni correction ( e ) and two-sided Mann-Whitney U test with a Bonferroni correction ( g , i , l , m ). Source data are provided as a Source Data file.
    Mouse Anti Human Pmlc2 Ser19, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/mouse anti human pmlc2 ser19/product/Cell Signaling Technology Inc
    Average 86 stars, based on 1 article reviews
    mouse anti human pmlc2 ser19 - by Bioz Stars, 2026-06
    86/100 stars

    Images

    1) Product Images from "Biomechanical control of vascular morphogenesis by the surrounding stiffness"

    Article Title: Biomechanical control of vascular morphogenesis by the surrounding stiffness

    Journal: Nature Communications

    doi: 10.1038/s41467-025-61804-z

    a – i Physical interventions altering lumen and branch expansions by externally loading intraluminal pressure in on-chip angiogenesis of ECs. a A schematic diagram showing the timeline of the loading and release cycles of intraluminal pressure. b , c Changes of lumens and branches when loaded followed by release of the additional intraluminal pressure. b Representative DIC images. White dotted lines indicate the proximal and distal boundaries of the analyzed luminal region. c Quantification of the changes in luminal area (loading: n = 12; release: n = 11, from 3 independent experiments). d – i Time-lapse analyses of on-chip angiogenesis during the intervention. d Representative serial DIC images at the elapsed time indicated at the top before and after loading and the release of additional intraluminal pressure (top, See also Supplementary Movie ) and kymograph of branch elongation (bottom). In the DIC images, yellow arrows and red lines indicate the trajectory of the tip of the branch and the tip EC displacement, respectively. In the kymograph, red and blue dotted lines indicate time points at which additional intraluminal pressure was loaded and then released, respectively. e Box plots of averaged branch elongation and the individual plots 3 h before (pressure change (−)) and after (load) the 1 st pressure loading and 3 h after its release (release) (left), and the corresponding box and individual plots in the control group without interventions (right) (pressure loading and release: n = 21 from 4 independent experiments, control: n = 19, from 3 independent experiments, See also Supplementary Fig. ). f – i Kymograph showing the dynamics of tip EC movement for 50 min before and 100 min after loading ( f ) and releasing ( h ) additional intraluminal pressure (time=0, dotted red line), and the quantification showing in box plots of averaged tip EC movement speed ( g , each group: n = 13 from 4 independent experiments; i , each group: n = 8 from 4 independent experiments). j – m Pharmacological interventions altering lumen and branch expansions of on-chip angiogenesis of ECs by treatment with Y27632 (top) and Blebbistatin (bottom), and without and with TG treatment of the gel. j Representative fluorescent images of the angiogenic branches. k Representative confocal z-projection images, with magnified images of square areas bound by dots (z-projection) and their corresponding confocal x-y slice images at specific z-portions (slice), showing localization pattern of pMLC2 in the angiogenic branches around the area where the de novo vascular lumen (yellow asterisks) develops. l , m , Box plots of branch length (left) and Tip expandability (right), without and with Y27632 ( l ) or Blebbistatin ( m ) and without and with TG treatment of the gel ( l , Y27632 (−) TG (−): n = 117; Y27632 ( + ) TG (−): n = 108; Y27632 ( + ) TG (+): n = 102, from 3 independent experiments, ( m ), Blebbistatin (−) TG (−): n = 39; Blebbistatin (+) TG (−): n = 35; Blebbistatin (+) TG (+): n = 64, from 3 independent experiments). All box plots show the interquartile range, with the middle line defining the median, and whiskers show the minimum and maximum values, excluding outliers ( g , i , l , m ). Outlier values are defined as being 1.5 times the interquartile range above and below the third and first quartile, respectively. Scale bars: 20 µm ( d , k ), 25 µm ( b ) and 100 µm ( j ). Two-sided Wilcoxon signed rank test ( c ), Wilcoxon signed rank test with a Bonferroni correction ( e ) and two-sided Mann-Whitney U test with a Bonferroni correction ( g , i , l , m ). Source data are provided as a Source Data file.
    Figure Legend Snippet: a – i Physical interventions altering lumen and branch expansions by externally loading intraluminal pressure in on-chip angiogenesis of ECs. a A schematic diagram showing the timeline of the loading and release cycles of intraluminal pressure. b , c Changes of lumens and branches when loaded followed by release of the additional intraluminal pressure. b Representative DIC images. White dotted lines indicate the proximal and distal boundaries of the analyzed luminal region. c Quantification of the changes in luminal area (loading: n = 12; release: n = 11, from 3 independent experiments). d – i Time-lapse analyses of on-chip angiogenesis during the intervention. d Representative serial DIC images at the elapsed time indicated at the top before and after loading and the release of additional intraluminal pressure (top, See also Supplementary Movie ) and kymograph of branch elongation (bottom). In the DIC images, yellow arrows and red lines indicate the trajectory of the tip of the branch and the tip EC displacement, respectively. In the kymograph, red and blue dotted lines indicate time points at which additional intraluminal pressure was loaded and then released, respectively. e Box plots of averaged branch elongation and the individual plots 3 h before (pressure change (−)) and after (load) the 1 st pressure loading and 3 h after its release (release) (left), and the corresponding box and individual plots in the control group without interventions (right) (pressure loading and release: n = 21 from 4 independent experiments, control: n = 19, from 3 independent experiments, See also Supplementary Fig. ). f – i Kymograph showing the dynamics of tip EC movement for 50 min before and 100 min after loading ( f ) and releasing ( h ) additional intraluminal pressure (time=0, dotted red line), and the quantification showing in box plots of averaged tip EC movement speed ( g , each group: n = 13 from 4 independent experiments; i , each group: n = 8 from 4 independent experiments). j – m Pharmacological interventions altering lumen and branch expansions of on-chip angiogenesis of ECs by treatment with Y27632 (top) and Blebbistatin (bottom), and without and with TG treatment of the gel. j Representative fluorescent images of the angiogenic branches. k Representative confocal z-projection images, with magnified images of square areas bound by dots (z-projection) and their corresponding confocal x-y slice images at specific z-portions (slice), showing localization pattern of pMLC2 in the angiogenic branches around the area where the de novo vascular lumen (yellow asterisks) develops. l , m , Box plots of branch length (left) and Tip expandability (right), without and with Y27632 ( l ) or Blebbistatin ( m ) and without and with TG treatment of the gel ( l , Y27632 (−) TG (−): n = 117; Y27632 ( + ) TG (−): n = 108; Y27632 ( + ) TG (+): n = 102, from 3 independent experiments, ( m ), Blebbistatin (−) TG (−): n = 39; Blebbistatin (+) TG (−): n = 35; Blebbistatin (+) TG (+): n = 64, from 3 independent experiments). All box plots show the interquartile range, with the middle line defining the median, and whiskers show the minimum and maximum values, excluding outliers ( g , i , l , m ). Outlier values are defined as being 1.5 times the interquartile range above and below the third and first quartile, respectively. Scale bars: 20 µm ( d , k ), 25 µm ( b ) and 100 µm ( j ). Two-sided Wilcoxon signed rank test ( c ), Wilcoxon signed rank test with a Bonferroni correction ( e ) and two-sided Mann-Whitney U test with a Bonferroni correction ( g , i , l , m ). Source data are provided as a Source Data file.

    Techniques Used: Control, MANN-WHITNEY



    Similar Products

    mouse anti human pmlc2 ser19  (Cell Signaling Technology Inc)
    86
    Cell Signaling Technology Inc mouse anti human pmlc2 ser19
    a – i Physical interventions altering lumen and branch expansions by externally loading intraluminal pressure in on-chip angiogenesis of ECs. a A schematic diagram showing the timeline of the loading and release cycles of intraluminal pressure. b , c Changes of lumens and branches when loaded followed by release of the additional intraluminal pressure. b Representative DIC images. White dotted lines indicate the proximal and distal boundaries of the analyzed luminal region. c Quantification of the changes in luminal area (loading: n = 12; release: n = 11, from 3 independent experiments). d – i Time-lapse analyses of on-chip angiogenesis during the intervention. d Representative serial DIC images at the elapsed time indicated at the top before and after loading and the release of additional intraluminal pressure (top, See also Supplementary Movie ) and kymograph of branch elongation (bottom). In the DIC images, yellow arrows and red lines indicate the trajectory of the tip of the branch and the tip EC displacement, respectively. In the kymograph, red and blue dotted lines indicate time points at which additional intraluminal pressure was loaded and then released, respectively. e Box plots of averaged branch elongation and the individual plots 3 h before (pressure change (−)) and after (load) the 1 st pressure loading and 3 h after its release (release) (left), and the corresponding box and individual plots in the control group without interventions (right) (pressure loading and release: n = 21 from 4 independent experiments, control: n = 19, from 3 independent experiments, See also Supplementary Fig. ). f – i Kymograph showing the dynamics of tip EC movement for 50 min before and 100 min after loading ( f ) and releasing ( h ) additional intraluminal pressure (time=0, dotted red line), and the quantification showing in box plots of averaged tip EC movement speed ( g , each group: n = 13 from 4 independent experiments; i , each group: n = 8 from 4 independent experiments). j – m Pharmacological interventions altering lumen and branch expansions of on-chip angiogenesis of ECs by treatment with Y27632 (top) and Blebbistatin (bottom), and without and with TG treatment of the gel. j Representative fluorescent images of the angiogenic branches. k Representative confocal z-projection images, with magnified images of square areas bound by dots (z-projection) and their corresponding confocal x-y slice images at specific z-portions (slice), showing localization pattern of <t>pMLC2</t> in the angiogenic branches around the area where the de novo vascular lumen (yellow asterisks) develops. l , m , Box plots of branch length (left) and Tip expandability (right), without and with Y27632 ( l ) or Blebbistatin ( m ) and without and with TG treatment of the gel ( l , Y27632 (−) TG (−): n = 117; Y27632 ( + ) TG (−): n = 108; Y27632 ( + ) TG (+): n = 102, from 3 independent experiments, ( m ), Blebbistatin (−) TG (−): n = 39; Blebbistatin (+) TG (−): n = 35; Blebbistatin (+) TG (+): n = 64, from 3 independent experiments). All box plots show the interquartile range, with the middle line defining the median, and whiskers show the minimum and maximum values, excluding outliers ( g , i , l , m ). Outlier values are defined as being 1.5 times the interquartile range above and below the third and first quartile, respectively. Scale bars: 20 µm ( d , k ), 25 µm ( b ) and 100 µm ( j ). Two-sided Wilcoxon signed rank test ( c ), Wilcoxon signed rank test with a Bonferroni correction ( e ) and two-sided Mann-Whitney U test with a Bonferroni correction ( g , i , l , m ). Source data are provided as a Source Data file.
    Mouse Anti Human Pmlc2 Ser19, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/mouse anti human pmlc2 ser19/product/Cell Signaling Technology Inc
    Average 86 stars, based on 1 article reviews
    mouse anti human pmlc2 ser19 - by Bioz Stars, 2026-06
    86/100 stars
    		  Buy from Supplier
    anti pmlc2 mouse monoclonal antibody  (Cell Signaling Technology Inc)
    86
    Cell Signaling Technology Inc anti pmlc2 mouse monoclonal antibody
    FIGURE 9 | ROCK phosphorylates MLC at the leading edge during neutrophil chemotaxis in a gradient of C5a. (a, e) Representative confocal images of PLB-985 cells treated with Y27632. Cells were uniformly stimulated with or without 3 nM C5a (a), or placed in a Zigmond chamber with a C5a gradient (e) in the absence (−) or presence (+) of 10 μM Y27632. Cells were then fixed with 3.7% formaldehyde and stained with the <t>anti-pMLC2</t> <t>(Ser19)</t> antibody, phalloidin, and Hoechst. (b, d) Quantification of Y27632-treated (b) or ROCK1/2-depleted (d) PLB-985 cells with uropod accu- mulation of pMLC2 induced by a uniform concentration of C5a. (c, g) Representative confocal images of PLB-985 cells. Cells transfected with the indicated RNA were uniformly stimulated for 90 s with 3 nM C5a (c), or placed in a Zigmond chamber with or without a C5a gradient (g). Cells were then fixed with 3.7% formaldehyde and stained with the indicated antibodies and Hoechst. The corresponding DIC images are also shown. (f, h) Quantification of Y27632-treated (f) or ROCK1/2-depleted (h) PLB-985 cells with pseudopod accumulation of pMLC2 in a C5a gradient. Values in b, d, f, and h are means ± SD from three independent experiments (n ≥ 100 cells/experiment). *p < 0.05; **p < 0.01; and ***p < 0.001 (Tukey–Kramer test). Scale bar = 10 μm.
    Anti Pmlc2 Mouse Monoclonal Antibody, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/anti pmlc2 mouse monoclonal antibody/product/Cell Signaling Technology Inc
    Average 86 stars, based on 1 article reviews
    anti pmlc2 mouse monoclonal antibody - by Bioz Stars, 2026-06
    86/100 stars
    		  Buy from Supplier
    anti phospho myosin light chain 2 pmlc2 s19 antibody  (Cell Signaling Technology Inc)
    96
    Cell Signaling Technology Inc anti phospho myosin light chain 2 pmlc2 s19 antibody
    In vivo <t>pMLC2</t> modulation. (A) Female, 8-week-old C57/BL6 mice (n = 8 per group) were dosed with indicated amounts of BLU4565 or BLU0556, respectively. Submandibular bleeds were taken one hour after dosing, and samples were analyzed by flow cytometry. Plasma samples were also taken to measure compound exposure. For pMLC2 flow cytometry, red blood cells were lysed, lymphocytes were stained with anti-CD3, and intracellular staining for pMLC2 was performed. (B) C57BL/6 mice (n = 6 per group) were dosed with BLU7482 (200 mg/kg QD or 50 mg/kg BID). Whole blood was collected through submandibular vein at 1 or 24 hours post treatment, followed by immunostaining and FACS analysis. Plasma samples were taken at 1 and 24 hours to determine compound exposure. Representative of n=3 experiments is shown. * P =0.0178, *** P =0.0003, **** P <0.001. BID, twice a day; CD, cluster of differentiation; EC 50 , half maximal effective concentration; IL-2, interleukin-2; MFI, mean fluorescence intensity; PD, pharmacodynamics; PK, pharmacokinetics; pMLC2, phospho-myosin light chain 2; P.O., orally; QD, daily.
    Anti Phospho Myosin Light Chain 2 Pmlc2 S19 Antibody, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/anti phospho myosin light chain 2 pmlc2 s19 antibody/product/Cell Signaling Technology Inc
    Average 96 stars, based on 1 article reviews
    anti phospho myosin light chain 2 pmlc2 s19 antibody - by Bioz Stars, 2026-06
    96/100 stars
    		  Buy from Supplier
    anti mouse pmlc2 s19  (Cell Signaling Technology Inc)
    96
    Cell Signaling Technology Inc anti mouse pmlc2 s19
    In vivo <t>pMLC2</t> modulation. (A) Female, 8-week-old C57/BL6 mice (n = 8 per group) were dosed with indicated amounts of BLU4565 or BLU0556, respectively. Submandibular bleeds were taken one hour after dosing, and samples were analyzed by flow cytometry. Plasma samples were also taken to measure compound exposure. For pMLC2 flow cytometry, red blood cells were lysed, lymphocytes were stained with anti-CD3, and intracellular staining for pMLC2 was performed. (B) C57BL/6 mice (n = 6 per group) were dosed with BLU7482 (200 mg/kg QD or 50 mg/kg BID). Whole blood was collected through submandibular vein at 1 or 24 hours post treatment, followed by immunostaining and FACS analysis. Plasma samples were taken at 1 and 24 hours to determine compound exposure. Representative of n=3 experiments is shown. * P =0.0178, *** P =0.0003, **** P <0.001. BID, twice a day; CD, cluster of differentiation; EC 50 , half maximal effective concentration; IL-2, interleukin-2; MFI, mean fluorescence intensity; PD, pharmacodynamics; PK, pharmacokinetics; pMLC2, phospho-myosin light chain 2; P.O., orally; QD, daily.
    Anti Mouse Pmlc2 S19, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/anti mouse pmlc2 s19/product/Cell Signaling Technology Inc
    Average 96 stars, based on 1 article reviews
    anti mouse pmlc2 s19 - by Bioz Stars, 2026-06
    96/100 stars
    		  Buy from Supplier
    anti pmlc2 ser19 mouse mab  (Cell Signaling Technology Inc)
    96
    Cell Signaling Technology Inc anti pmlc2 ser19 mouse mab
    In vivo <t>pMLC2</t> modulation. (A) Female, 8-week-old C57/BL6 mice (n = 8 per group) were dosed with indicated amounts of BLU4565 or BLU0556, respectively. Submandibular bleeds were taken one hour after dosing, and samples were analyzed by flow cytometry. Plasma samples were also taken to measure compound exposure. For pMLC2 flow cytometry, red blood cells were lysed, lymphocytes were stained with anti-CD3, and intracellular staining for pMLC2 was performed. (B) C57BL/6 mice (n = 6 per group) were dosed with BLU7482 (200 mg/kg QD or 50 mg/kg BID). Whole blood was collected through submandibular vein at 1 or 24 hours post treatment, followed by immunostaining and FACS analysis. Plasma samples were taken at 1 and 24 hours to determine compound exposure. Representative of n=3 experiments is shown. * P =0.0178, *** P =0.0003, **** P <0.001. BID, twice a day; CD, cluster of differentiation; EC 50 , half maximal effective concentration; IL-2, interleukin-2; MFI, mean fluorescence intensity; PD, pharmacodynamics; PK, pharmacokinetics; pMLC2, phospho-myosin light chain 2; P.O., orally; QD, daily.
    Anti Pmlc2 Ser19 Mouse Mab, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/anti pmlc2 ser19 mouse mab/product/Cell Signaling Technology Inc
    Average 96 stars, based on 1 article reviews
    anti pmlc2 ser19 mouse mab - by Bioz Stars, 2026-06
    96/100 stars
    		  Buy from Supplier
    pmlc2  (Cell Signaling Technology Inc)
    96
    Cell Signaling Technology Inc pmlc2
    In vivo <t>pMLC2</t> modulation. (A) Female, 8-week-old C57/BL6 mice (n = 8 per group) were dosed with indicated amounts of BLU4565 or BLU0556, respectively. Submandibular bleeds were taken one hour after dosing, and samples were analyzed by flow cytometry. Plasma samples were also taken to measure compound exposure. For pMLC2 flow cytometry, red blood cells were lysed, lymphocytes were stained with anti-CD3, and intracellular staining for pMLC2 was performed. (B) C57BL/6 mice (n = 6 per group) were dosed with BLU7482 (200 mg/kg QD or 50 mg/kg BID). Whole blood was collected through submandibular vein at 1 or 24 hours post treatment, followed by immunostaining and FACS analysis. Plasma samples were taken at 1 and 24 hours to determine compound exposure. Representative of n=3 experiments is shown. * P =0.0178, *** P =0.0003, **** P <0.001. BID, twice a day; CD, cluster of differentiation; EC 50 , half maximal effective concentration; IL-2, interleukin-2; MFI, mean fluorescence intensity; PD, pharmacodynamics; PK, pharmacokinetics; pMLC2, phospho-myosin light chain 2; P.O., orally; QD, daily.
    Pmlc2, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/pmlc2/product/Cell Signaling Technology Inc
    Average 96 stars, based on 1 article reviews
    pmlc2 - by Bioz Stars, 2026-06
    96/100 stars
    		  Buy from Supplier
    pmlc2 ser19  (Cell Signaling Technology Inc)
    96
    Cell Signaling Technology Inc pmlc2 ser19
    In vivo <t>pMLC2</t> modulation. (A) Female, 8-week-old C57/BL6 mice (n = 8 per group) were dosed with indicated amounts of BLU4565 or BLU0556, respectively. Submandibular bleeds were taken one hour after dosing, and samples were analyzed by flow cytometry. Plasma samples were also taken to measure compound exposure. For pMLC2 flow cytometry, red blood cells were lysed, lymphocytes were stained with anti-CD3, and intracellular staining for pMLC2 was performed. (B) C57BL/6 mice (n = 6 per group) were dosed with BLU7482 (200 mg/kg QD or 50 mg/kg BID). Whole blood was collected through submandibular vein at 1 or 24 hours post treatment, followed by immunostaining and FACS analysis. Plasma samples were taken at 1 and 24 hours to determine compound exposure. Representative of n=3 experiments is shown. * P =0.0178, *** P =0.0003, **** P <0.001. BID, twice a day; CD, cluster of differentiation; EC 50 , half maximal effective concentration; IL-2, interleukin-2; MFI, mean fluorescence intensity; PD, pharmacodynamics; PK, pharmacokinetics; pMLC2, phospho-myosin light chain 2; P.O., orally; QD, daily.
    Pmlc2 Ser19, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/pmlc2 ser19/product/Cell Signaling Technology Inc
    Average 96 stars, based on 1 article reviews
    pmlc2 ser19 - by Bioz Stars, 2026-06
    96/100 stars
    		  Buy from Supplier

    Image Search Results


    a – i Physical interventions altering lumen and branch expansions by externally loading intraluminal pressure in on-chip angiogenesis of ECs. a A schematic diagram showing the timeline of the loading and release cycles of intraluminal pressure. b , c Changes of lumens and branches when loaded followed by release of the additional intraluminal pressure. b Representative DIC images. White dotted lines indicate the proximal and distal boundaries of the analyzed luminal region. c Quantification of the changes in luminal area (loading: n = 12; release: n = 11, from 3 independent experiments). d – i Time-lapse analyses of on-chip angiogenesis during the intervention. d Representative serial DIC images at the elapsed time indicated at the top before and after loading and the release of additional intraluminal pressure (top, See also Supplementary Movie ) and kymograph of branch elongation (bottom). In the DIC images, yellow arrows and red lines indicate the trajectory of the tip of the branch and the tip EC displacement, respectively. In the kymograph, red and blue dotted lines indicate time points at which additional intraluminal pressure was loaded and then released, respectively. e Box plots of averaged branch elongation and the individual plots 3 h before (pressure change (−)) and after (load) the 1 st pressure loading and 3 h after its release (release) (left), and the corresponding box and individual plots in the control group without interventions (right) (pressure loading and release: n = 21 from 4 independent experiments, control: n = 19, from 3 independent experiments, See also Supplementary Fig. ). f – i Kymograph showing the dynamics of tip EC movement for 50 min before and 100 min after loading ( f ) and releasing ( h ) additional intraluminal pressure (time=0, dotted red line), and the quantification showing in box plots of averaged tip EC movement speed ( g , each group: n = 13 from 4 independent experiments; i , each group: n = 8 from 4 independent experiments). j – m Pharmacological interventions altering lumen and branch expansions of on-chip angiogenesis of ECs by treatment with Y27632 (top) and Blebbistatin (bottom), and without and with TG treatment of the gel. j Representative fluorescent images of the angiogenic branches. k Representative confocal z-projection images, with magnified images of square areas bound by dots (z-projection) and their corresponding confocal x-y slice images at specific z-portions (slice), showing localization pattern of pMLC2 in the angiogenic branches around the area where the de novo vascular lumen (yellow asterisks) develops. l , m , Box plots of branch length (left) and Tip expandability (right), without and with Y27632 ( l ) or Blebbistatin ( m ) and without and with TG treatment of the gel ( l , Y27632 (−) TG (−): n = 117; Y27632 ( + ) TG (−): n = 108; Y27632 ( + ) TG (+): n = 102, from 3 independent experiments, ( m ), Blebbistatin (−) TG (−): n = 39; Blebbistatin (+) TG (−): n = 35; Blebbistatin (+) TG (+): n = 64, from 3 independent experiments). All box plots show the interquartile range, with the middle line defining the median, and whiskers show the minimum and maximum values, excluding outliers ( g , i , l , m ). Outlier values are defined as being 1.5 times the interquartile range above and below the third and first quartile, respectively. Scale bars: 20 µm ( d , k ), 25 µm ( b ) and 100 µm ( j ). Two-sided Wilcoxon signed rank test ( c ), Wilcoxon signed rank test with a Bonferroni correction ( e ) and two-sided Mann-Whitney U test with a Bonferroni correction ( g , i , l , m ). Source data are provided as a Source Data file.

    Journal: Nature Communications

    Article Title: Biomechanical control of vascular morphogenesis by the surrounding stiffness

    doi: 10.1038/s41467-025-61804-z

    Figure Lengend Snippet: a – i Physical interventions altering lumen and branch expansions by externally loading intraluminal pressure in on-chip angiogenesis of ECs. a A schematic diagram showing the timeline of the loading and release cycles of intraluminal pressure. b , c Changes of lumens and branches when loaded followed by release of the additional intraluminal pressure. b Representative DIC images. White dotted lines indicate the proximal and distal boundaries of the analyzed luminal region. c Quantification of the changes in luminal area (loading: n = 12; release: n = 11, from 3 independent experiments). d – i Time-lapse analyses of on-chip angiogenesis during the intervention. d Representative serial DIC images at the elapsed time indicated at the top before and after loading and the release of additional intraluminal pressure (top, See also Supplementary Movie ) and kymograph of branch elongation (bottom). In the DIC images, yellow arrows and red lines indicate the trajectory of the tip of the branch and the tip EC displacement, respectively. In the kymograph, red and blue dotted lines indicate time points at which additional intraluminal pressure was loaded and then released, respectively. e Box plots of averaged branch elongation and the individual plots 3 h before (pressure change (−)) and after (load) the 1 st pressure loading and 3 h after its release (release) (left), and the corresponding box and individual plots in the control group without interventions (right) (pressure loading and release: n = 21 from 4 independent experiments, control: n = 19, from 3 independent experiments, See also Supplementary Fig. ). f – i Kymograph showing the dynamics of tip EC movement for 50 min before and 100 min after loading ( f ) and releasing ( h ) additional intraluminal pressure (time=0, dotted red line), and the quantification showing in box plots of averaged tip EC movement speed ( g , each group: n = 13 from 4 independent experiments; i , each group: n = 8 from 4 independent experiments). j – m Pharmacological interventions altering lumen and branch expansions of on-chip angiogenesis of ECs by treatment with Y27632 (top) and Blebbistatin (bottom), and without and with TG treatment of the gel. j Representative fluorescent images of the angiogenic branches. k Representative confocal z-projection images, with magnified images of square areas bound by dots (z-projection) and their corresponding confocal x-y slice images at specific z-portions (slice), showing localization pattern of pMLC2 in the angiogenic branches around the area where the de novo vascular lumen (yellow asterisks) develops. l , m , Box plots of branch length (left) and Tip expandability (right), without and with Y27632 ( l ) or Blebbistatin ( m ) and without and with TG treatment of the gel ( l , Y27632 (−) TG (−): n = 117; Y27632 ( + ) TG (−): n = 108; Y27632 ( + ) TG (+): n = 102, from 3 independent experiments, ( m ), Blebbistatin (−) TG (−): n = 39; Blebbistatin (+) TG (−): n = 35; Blebbistatin (+) TG (+): n = 64, from 3 independent experiments). All box plots show the interquartile range, with the middle line defining the median, and whiskers show the minimum and maximum values, excluding outliers ( g , i , l , m ). Outlier values are defined as being 1.5 times the interquartile range above and below the third and first quartile, respectively. Scale bars: 20 µm ( d , k ), 25 µm ( b ) and 100 µm ( j ). Two-sided Wilcoxon signed rank test ( c ), Wilcoxon signed rank test with a Bonferroni correction ( e ) and two-sided Mann-Whitney U test with a Bonferroni correction ( g , i , l , m ). Source data are provided as a Source Data file.

    Article Snippet: The antibodies used were as follows: mouse anti-human CD31 (WM59, BioLegend, 303102), rabbit anti-human PDGFRβ (Y92, OriGene), rabbit anti-GOLPH4 (Abcam, ab28049), rabbit anti-VE-cadherin (D87F2, Cell Signaling, 2500), goat anti-collagen type IV (SouthernBiotech, 1340-01), rabbit anti-laminin (Abcam, ab11575), rabbit anti-NG2 (Millipore, AB5320), rat anti-mouse CD31 (MEC13.3, BD Pharmingen, 552074), rat anti-ICAM2 (3C4, BioLegend, 105601), goat anti-human ARPC2 (Novus Biologicals, NB100-137), rabbit anti-human TRIP10 (CIP4, Proteintech, 10798-1-AP), mouse anti-human pMLC2 (Ser19) (Cell Signaling, #3675), rabbit anti-human Moesin (EPR3864, Abcam, ab52490), Alexa Fluor 488-conjugated rabbit anti-ERG2 (EPR3864, Abcam, ab196374), Alexa Fluor 488-conjugated goat anti-mouse IgG and goat anti-rat IgG (Thermo Fischer Scientific), Cy3-conjugated goat anti-rabbit IgG and goat anti-rat IgG (Thermo Fischer Scientific) and Cy3-conjugated donkey anti-rabbit IgG (Thermo Fischer Scientific).

    Techniques: Control, MANN-WHITNEY

    FIGURE 9 | ROCK phosphorylates MLC at the leading edge during neutrophil chemotaxis in a gradient of C5a. (a, e) Representative confocal images of PLB-985 cells treated with Y27632. Cells were uniformly stimulated with or without 3 nM C5a (a), or placed in a Zigmond chamber with a C5a gradient (e) in the absence (−) or presence (+) of 10 μM Y27632. Cells were then fixed with 3.7% formaldehyde and stained with the anti-pMLC2 (Ser19) antibody, phalloidin, and Hoechst. (b, d) Quantification of Y27632-treated (b) or ROCK1/2-depleted (d) PLB-985 cells with uropod accu- mulation of pMLC2 induced by a uniform concentration of C5a. (c, g) Representative confocal images of PLB-985 cells. Cells transfected with the indicated RNA were uniformly stimulated for 90 s with 3 nM C5a (c), or placed in a Zigmond chamber with or without a C5a gradient (g). Cells were then fixed with 3.7% formaldehyde and stained with the indicated antibodies and Hoechst. The corresponding DIC images are also shown. (f, h) Quantification of Y27632-treated (f) or ROCK1/2-depleted (h) PLB-985 cells with pseudopod accumulation of pMLC2 in a C5a gradient. Values in b, d, f, and h are means ± SD from three independent experiments (n ≥ 100 cells/experiment). *p < 0.05; **p < 0.01; and ***p < 0.001 (Tukey–Kramer test). Scale bar = 10 μm.

    Journal: Genes to cells : devoted to molecular & cellular mechanisms

    Article Title: The Protein Kinase aPKC as Well as the Small GTPases RhoA and Cdc42 Regulates Neutrophil Chemotaxis Partly by Recruiting the ROCK Kinase to the Leading Edge.

    doi: 10.1111/gtc.70002

    Figure Lengend Snippet: FIGURE 9 | ROCK phosphorylates MLC at the leading edge during neutrophil chemotaxis in a gradient of C5a. (a, e) Representative confocal images of PLB-985 cells treated with Y27632. Cells were uniformly stimulated with or without 3 nM C5a (a), or placed in a Zigmond chamber with a C5a gradient (e) in the absence (−) or presence (+) of 10 μM Y27632. Cells were then fixed with 3.7% formaldehyde and stained with the anti-pMLC2 (Ser19) antibody, phalloidin, and Hoechst. (b, d) Quantification of Y27632-treated (b) or ROCK1/2-depleted (d) PLB-985 cells with uropod accu- mulation of pMLC2 induced by a uniform concentration of C5a. (c, g) Representative confocal images of PLB-985 cells. Cells transfected with the indicated RNA were uniformly stimulated for 90 s with 3 nM C5a (c), or placed in a Zigmond chamber with or without a C5a gradient (g). Cells were then fixed with 3.7% formaldehyde and stained with the indicated antibodies and Hoechst. The corresponding DIC images are also shown. (f, h) Quantification of Y27632-treated (f) or ROCK1/2-depleted (h) PLB-985 cells with pseudopod accumulation of pMLC2 in a C5a gradient. Values in b, d, f, and h are means ± SD from three independent experiments (n ≥ 100 cells/experiment). *p < 0.05; **p < 0.01; and ***p < 0.001 (Tukey–Kramer test). Scale bar = 10 μm.

    Article Snippet: The anti- Cdc42 (44; #610929) and anti- PKCι/λ (41; #610207) mouse monoclonal antibodies were purchased from BD Transduction Laboratory; the anti- RhoA (26C4; #sc- 418), anti- GAPDH (0411; #sc- 47724), and anti- β- actin (C4; #sc- 47778) mouse monoclonal antibodies from Santa Cruz Biotechnology; the anti- RhoA mouse monoclonal antibody (1B12; #ab54835), the anti- ROCK1 rabbit monoclonal antibody (EPR638Y; #ab134181), and anti- ROCK2 rabbit polyclonal antibody (#ab71598) from Abcam; the antiFLAG mouse monoclonal antibody (M2; #F1804) and anti- FLAG rabbit polyclonal antibody (#F7425) from Sigma- Aldrich; the antiMyc mouse monoclonal antibody (9E10; #11667203001) from Roche Applied Science; and the anti- phospho- Ser- PKC substrate (#2261) and anti- phospho- MLC2 (pMLC) (Thr18/Ser19; #3674) rabbit polyclonal antibodies, the anti- pMLC2 mouse monoclonal antibody (Ser19; #3675), and the anti- phospho- ezrin (Thr567)/ radixin (Thr564)/moesin (Thr558) (pERM) rabbit monoclonal antibody (48G2; #3726) from Cell Signaling Technology.

    Techniques: Chemotaxis Assay, Staining, Concentration Assay, Transfection

    In vivo pMLC2 modulation. (A) Female, 8-week-old C57/BL6 mice (n = 8 per group) were dosed with indicated amounts of BLU4565 or BLU0556, respectively. Submandibular bleeds were taken one hour after dosing, and samples were analyzed by flow cytometry. Plasma samples were also taken to measure compound exposure. For pMLC2 flow cytometry, red blood cells were lysed, lymphocytes were stained with anti-CD3, and intracellular staining for pMLC2 was performed. (B) C57BL/6 mice (n = 6 per group) were dosed with BLU7482 (200 mg/kg QD or 50 mg/kg BID). Whole blood was collected through submandibular vein at 1 or 24 hours post treatment, followed by immunostaining and FACS analysis. Plasma samples were taken at 1 and 24 hours to determine compound exposure. Representative of n=3 experiments is shown. * P =0.0178, *** P =0.0003, **** P <0.001. BID, twice a day; CD, cluster of differentiation; EC 50 , half maximal effective concentration; IL-2, interleukin-2; MFI, mean fluorescence intensity; PD, pharmacodynamics; PK, pharmacokinetics; pMLC2, phospho-myosin light chain 2; P.O., orally; QD, daily.

    Journal: Frontiers in Immunology

    Article Title: Evaluation of STK17B as a cancer immunotherapy target utilizing highly potent and selective small molecule inhibitors

    doi: 10.3389/fimmu.2024.1411395

    Figure Lengend Snippet: In vivo pMLC2 modulation. (A) Female, 8-week-old C57/BL6 mice (n = 8 per group) were dosed with indicated amounts of BLU4565 or BLU0556, respectively. Submandibular bleeds were taken one hour after dosing, and samples were analyzed by flow cytometry. Plasma samples were also taken to measure compound exposure. For pMLC2 flow cytometry, red blood cells were lysed, lymphocytes were stained with anti-CD3, and intracellular staining for pMLC2 was performed. (B) C57BL/6 mice (n = 6 per group) were dosed with BLU7482 (200 mg/kg QD or 50 mg/kg BID). Whole blood was collected through submandibular vein at 1 or 24 hours post treatment, followed by immunostaining and FACS analysis. Plasma samples were taken at 1 and 24 hours to determine compound exposure. Representative of n=3 experiments is shown. * P =0.0178, *** P =0.0003, **** P <0.001. BID, twice a day; CD, cluster of differentiation; EC 50 , half maximal effective concentration; IL-2, interleukin-2; MFI, mean fluorescence intensity; PD, pharmacodynamics; PK, pharmacokinetics; pMLC2, phospho-myosin light chain 2; P.O., orally; QD, daily.

    Article Snippet: Cells were then incubated with anti-phospho-myosin light chain 2 (pMLC2) S19 antibody (Cell Signaling Technology Cat# CST 3675, Lot #5) diluted 1:400 in Perm/Wash buffer for one hour on ice in the dark.

    Techniques: In Vivo, Flow Cytometry, Clinical Proteomics, Staining, Immunostaining, Concentration Assay, Fluorescence, Drug discovery